Trial Outcomes & Findings for Human Biological Responses to Low Level Ozone (NCT NCT02857283)
NCT ID: NCT02857283
Last Updated: 2021-05-14
Results Overview
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Nasal lavage fluid (NLF) will be collected from participants at a baseline visit within two weeks prior to each exposure, and at the following time points for each exposure: immediately after exiting the exposure chamber, and at 24 hours after the exposure. The % PMN as a percentage of total inflammatory cells (total of monocytes and macrophages, PMN, eosinophils, basophils, lymphocytes, and bronchial epithelial cells) will be determined in each NLF collection by differential counts of cells on cytospin slides. The change in the values from baseline to immediately Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3.
COMPLETED
NA
15 participants
Baseline, immediately post-exposure
2021-05-14
Participant Flow
A total of 17 participants were screened between April 22, 2017 and May 1, 2019. Participants were recruited from a database of subjects at the Center for Environmental Medicine, Asthma and Lung Biology.
Two participants did not meet inclusion criteria, and 1 withdrew before undergoing the second exposure. All participants were free from acute illness
Participant milestones
| Measure |
Filtered Air; Then Ozone
Participants were exposed to filtered clean air for 6.5 hours, and after a minimum of a 2-week washout, they returned and were exposed to 0.06-0.08 Parts Per Million (PPM) ozone for 6.5 hours. All participants wore a Health and Exposure Tracker (HET): Ozone and heart rate tracker during both exposures.
|
Ozone; Then Filtered Air
Participants were exposed to 0.06-0.08 PPM ozone for 6.5 hours, and after a minimum of a 2-week washout, they returned and were exposed to filtered clean air for 6.5 hours. All participants wore a Health and Exposure Tracker (HET): Ozone and heart rate tracker during both exposures.
|
|---|---|---|
|
First Exposure
STARTED
|
8
|
7
|
|
First Exposure
COMPLETED
|
7
|
7
|
|
First Exposure
NOT COMPLETED
|
1
|
0
|
|
Washout (2 Weeks)
STARTED
|
7
|
7
|
|
Washout (2 Weeks)
COMPLETED
|
7
|
7
|
|
Washout (2 Weeks)
NOT COMPLETED
|
0
|
0
|
|
Second Exposure
STARTED
|
7
|
7
|
|
Second Exposure
COMPLETED
|
7
|
7
|
|
Second Exposure
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
| Measure |
Filtered Air; Then Ozone
Participants were exposed to filtered clean air for 6.5 hours, and after a minimum of a 2-week washout, they returned and were exposed to 0.06-0.08 Parts Per Million (PPM) ozone for 6.5 hours. All participants wore a Health and Exposure Tracker (HET): Ozone and heart rate tracker during both exposures.
|
Ozone; Then Filtered Air
Participants were exposed to 0.06-0.08 PPM ozone for 6.5 hours, and after a minimum of a 2-week washout, they returned and were exposed to filtered clean air for 6.5 hours. All participants wore a Health and Exposure Tracker (HET): Ozone and heart rate tracker during both exposures.
|
|---|---|---|
|
First Exposure
Withdrawal by Subject
|
1
|
0
|
Baseline Characteristics
Human Biological Responses to Low Level Ozone
Baseline characteristics by cohort
| Measure |
Filtered Air; Then Ozone
n=7 Participants
Participants were exposed to filtered clean air for 6.5 hours, and after a minimum of a 2-week washout, they returned and were exposed to 0.06-0.08 PPM ozone for 6.5 hours. All participants wore a Health and Exposure Tracker (HET): Ozone and heart rate tracker during both exposures
|
Ozone; Then Filtered Air
n=7 Participants
Participants were exposed to 0.06-0.08 PPM ozone for 6.5 hours, and after a minimum of a 2-week washout, they returned and were exposed to filtered clean air for 6.5 hours. All participants wore a Health and Exposure Tracker (HET): Ozone and heart rate tracker during both exposures
|
Total
n=14 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
28.8 years
n=99 Participants
|
35.47 years
n=107 Participants
|
31.22 years
n=206 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
6 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
6 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
7 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline, immediately post-exposurePopulation: Only 5 participants had paired pre and immediately post-filtered air exposure samples and only 3 had paired pre and immediately post-ozone exposure samples of adequate quality for analysis. Only 1 participant had paired samples from both exposure periods. The remainder of samples were of poor quality and contained insufficient cells for analysis.
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Nasal lavage fluid (NLF) will be collected from participants at a baseline visit within two weeks prior to each exposure, and at the following time points for each exposure: immediately after exiting the exposure chamber, and at 24 hours after the exposure. The % PMN as a percentage of total inflammatory cells (total of monocytes and macrophages, PMN, eosinophils, basophils, lymphocytes, and bronchial epithelial cells) will be determined in each NLF collection by differential counts of cells on cytospin slides. The change in the values from baseline to immediately Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3.
Outcome measures
| Measure |
Filtered Air
n=5 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=3 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid Immediately Post-Exposure From Baseline
|
-1.02 percent PMNs in nasal lavage fluid
Standard Error 10.57
|
-6.8 percent PMNs in nasal lavage fluid
Standard Error 6.75
|
PRIMARY outcome
Timeframe: Baseline, 24 hours post-exposurePopulation: Only 5 participants had paired pre and 24h post-filtered air exposure samples and only 3 had paired pre and 24h post-ozone exposure samples of adequate quality for analysis. Only 1 participant had paired samples from both exposure periods. The remainder of samples were of poor quality and contained insufficient cells for analysis.
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Nasal lavage fluid (NLF) will be collected from participants at a baseline visit within two weeks prior to each exposure, and at the following time points for each exposure: immediately after exiting the exposure chamber, and at 24 hours after the exposure. The % PMN as a percentage of total inflammatory cells (total of monocytes and macrophages, PMN, eosinophils, basophils, lymphocytes, and bronchial epithelial cells) will be determined in each NLF collection by differential counts of cells on cytospin slides. The change in the values from baseline to 24 hours Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3.
Outcome measures
| Measure |
Filtered Air
n=5 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=3 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid 24 Hours Post-Exposure From Baseline
|
17.18 percent PMNs in nasal lavage fluid
Standard Error 16.76
|
-27.97 percent PMNs in nasal lavage fluid
Standard Error 31.67
|
SECONDARY outcome
Timeframe: Baseline, immediately post-exposurePopulation: All participants that completed the study
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Nasal epithelial lining (ELF) will be collected from participants at a baseline visit within two weeks prior to each exposure, and at the following time points for each exposure: immediately after exiting the exposure chamber, and at 24 hours after the exposure. The IL-6 concentration will be determined in each ELF sample by immunoassay. The change in IL-6 concentrations from baseline to immediately Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3 to determine the effect of ozone on the production of nasal IL-6.
Outcome measures
| Measure |
Filtered Air
n=14 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=14 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Interleukin-6 (IL-6) Concentrations in Nasal Epithelial Lining Fluid (ELF): Change Immediately Post-Exposure From Baseline
|
2.28 pg/mL
Standard Error 2.01
|
5.33 pg/mL
Standard Error 3.19
|
SECONDARY outcome
Timeframe: Screening visit and 24 hours post-exposurePopulation: Participants who produced induced sputum containing at least 60000 inflammatory cells at both the screening visit and at 24 hours after at least one exposure
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Induced sputum will be collected from participants after inhaled hypertonic saline. Induced sputum will be collected at the screening visit within six weeks prior to the first exposure, and at 24 hours after each exposure. The % PMN as a percentage of total inflammatory cells (total of monocytes and macrophages, PMN, eosinophils, basophils, lymphocytes, and bronchial epithelial cells) will be determined in each induced sputum collection by differential counts of cells on cytospin slides. The change in the values from baseline to 24 hours Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3.
Outcome measures
| Measure |
Filtered Air
n=9 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=10 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
% Polymorphonuclear Leukocytes (PMN) in Induced Sputum: Change 24 Hours Post-Exposure From Screening Visit
|
12.04 percent PMN
Standard Error 5.22
|
21.86 percent PMN
Standard Error 7.74
|
SECONDARY outcome
Timeframe: Baseline, immediately post-exposurePopulation: All participants that completed the study
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Standard spirometry to obtain FEV1 and forced vital capacity (FVC) measurements will be done at baseline within two weeks prior to first exposure, and immediately after exiting the exposure chamber for each exposure. The % Predicted FEV1 will be calculated from measured versus expected values. The change in % Predicted FEV1 from baseline to immediately Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3 to determine the effect of ozone on the % Predicted FEV1.
Outcome measures
| Measure |
Filtered Air
n=14 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=14 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
The Percentage of Predicted Forced Expiratory Volume in One Second (% Predicted FEV1): Change Immediately Post-Exposure From Baseline
|
0.79 percent predicted FEV1
Standard Error 0.70
|
-2.00 percent predicted FEV1
Standard Error 0.70
|
SECONDARY outcome
Timeframe: Baseline, 24 hours post-exposurePopulation: All participants that completed the study
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Nasal epithelial lining (ELF) will be collected from participants at baseline within two weeks prior to first exposure, and at the following time points for each exposure: immediately after exiting the exposure chamber, and at 24 hours after the exposure. The IL-6 concentration will be determined in each ELF sample by immunoassay. The change in IL-6 concentrations from baseline to 24 hours Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3 to determine the effect of ozone on the production of nasal IL-6.
Outcome measures
| Measure |
Filtered Air
n=14 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=14 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Interleukin-6 (IL-6) Concentrations in Nasal Epithelial Lining Fluid (ELF): Change 24 Hours Post-Exposure From Baseline
|
4.15 pg/ml
Standard Error 2.57
|
11.25 pg/ml
Standard Error 3.56
|
SECONDARY outcome
Timeframe: Baseline, immediately post-exposurePopulation: All participants that completed the study
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Nasal epithelial lining (ELF) will be collected from participants at baseline within two weeks prior to first exposure, and at the following time points for each exposure: immediately after exiting the exposure chamber, and at 24 hours after the exposure. The IL-8 concentration will be determined in each ELF sample by immunoassay. The change in IL-8 concentrations from baseline to immediately Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3 to determine the effect of ozone on the production of nasal IL-8.
Outcome measures
| Measure |
Filtered Air
n=14 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=14 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Interleukin-8 (IL-8) Concentrations in Nasal Epithelial Lining Fluid (ELF): Change Immediately Post-Exposure From Baseline
|
2036.75 pg/mL
Standard Error 1518.94
|
2939.08 pg/mL
Standard Error 1885.08
|
SECONDARY outcome
Timeframe: Baseline, 24 hours post-exposurePopulation: All participants that completed the study
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Nasal epithelial lining (ELF) will be collected from participants at baseline within two weeks prior to first exposure, and at the following time points for each exposure: immediately after exiting the exposure chamber, and at 24 hours after the exposure. The IL-8 concentration will be determined in each ELF sample by immunoassay. The change in IL-8 concentrations from baseline to 24 hours Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3 to determine the effect of ozone on the production of nasal IL-8.
Outcome measures
| Measure |
Filtered Air
n=14 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=14 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Interleukin-8 (IL-8) Concentrations in Nasal Epithelial Lining Fluid (ELF): Change 24 Hours Post-Exposure From Baseline
|
3524.77 pg/mL
Standard Error 2165.80
|
6696.56 pg/mL
Standard Error 3032.59
|
SECONDARY outcome
Timeframe: Baseline and immediately post-exposurePopulation: One participant's LVS data was collected but was not able to undergo analysis due to the shutdown of university laboratories in response to the pandemic
Left ventricular strain will be assessed at baseline prior to exposure (within two weeks), and immediately after the exposure by measuring global longitudinal strain (GLS), an echocardiographic measure of myocardial mechanics. GLS is measured using speckle tracking, a technique by which small myocardial footprints, or speckles, are tracked over the cardiac cycle to enable quantification of left ventricular systolic function. GLS is more sensitive than traditional measures of ventricular function, such as ejection fraction, in detecting clinically inapparent but prognostically important decrements in contractility. The change in global longitudinal strain will be calculated to determine the effect of ozone on left ventricular strain.
Outcome measures
| Measure |
Filtered Air
n=13 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=13 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Left Ventricular Strain (LVS): Change Immediately Post-Exposure From Baseline
|
0.58 percent change
Standard Error 0.44
|
0.06 percent change
Standard Error 0.63
|
SECONDARY outcome
Timeframe: Screening visit and immediately post-exposurePopulation: One participant did not have a pre-exposure nasal epithelial cell biopsy sample available for analysis.
RNA isolated from nasal epithelial cell biopsies collected at the screening visit (baseline) within six weeks prior to the first exposure and immediately after each exposure. RNA will be analyzed via real-time quantitative polymerase chain reaction (qPCR) to determine the impact of O3 on inflammatory gene expression.
Outcome measures
| Measure |
Filtered Air
n=13 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=13 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Nasal Epithelial Cell IL-1 Beta Gene Expression: Relative mRNA Counts Immediately Post-Exposure (Baseline-corrected), Ozone vs Filtered Air
|
-169.6 relative mRNA counts
Standard Deviation 317.5
|
-147.4 relative mRNA counts
Standard Deviation 329.1
|
SECONDARY outcome
Timeframe: Baseline and immediately post-exposurePopulation: All participants that completed the study
Participants will undergo assesment of flow-mediated brachial artery dilation by brachial ultrasound at baseline prior to exposure (within two weeks), and immediately after exposure to either FA or O3 to assess the impact of O3 exposure on endothelial function. Flow mediated dilation of the brachial artery (FMD) is a noninvasive index of vascular endothelial function. FMD is measured using high-frequency ultrasound, and is expressed as the percent change in arterial diameter in response to the reactive hyperemia induced by 5 minutes of forearm ischemia. Impaired endothelial function leads to atherosclerosis and is associated with an increased risk of cardiovascular events.
Outcome measures
| Measure |
Filtered Air
n=14 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=14 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Flow Mediated Dilation (FMD): Change Immediately Post-Exposure From Baseline
|
1.09 percent change
Standard Error 1.02
|
1.25 percent change
Standard Error 1.04
|
SECONDARY outcome
Timeframe: baseline, immediately post exposurePopulation: No participants analyzed as equipment belonging to the EPA was not available
Measure was not performed as the equipment (ECG leads and monitor recording heart rate and rhythm) belonged to the EPA and was not made available for this study
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Screening visit and immediately post-exposurePopulation: One participant did not have a pre-exposure nasal epithelial cell biopsy sample available for analysis.
RNA isolated from nasal epithelial cell biopsies collected at the screening visit (baseline) within six weeks prior to the first exposure and immediately after each exposure. RNA will be analyzed via real-time quantitative polymerase chain reaction (qPCR) to determine the impact of O3 on inflammatory gene expression.
Outcome measures
| Measure |
Filtered Air
n=13 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=13 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Nasal Epithelial Cell IL-6R Gene Expression: Relative mRNA Counts Immediately Post-Exposure (Baseline-corrected), Ozone vs Filtered Air
|
-10.22 relative mRNA counts
Standard Deviation 38.5
|
-4.72 relative mRNA counts
Standard Deviation 25.77
|
SECONDARY outcome
Timeframe: Screening visit and immediately post-exposurePopulation: One participant did not have a pre-exposure nasal epithelial cell biopsy sample available for analysis.
RNA isolated from nasal epithelial cell biopsies collected at the screening visit (baseline) within six weeks prior to the first exposure and immediately after each exposure. RNA will be analyzed via real-time quantitative polymerase chain reaction (qPCR) to determine the impact of O3 on inflammatory gene expression.
Outcome measures
| Measure |
Filtered Air
n=13 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=13 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
Nasal Epithelial Cell IL-8 Gene Expression: Relative mRNA Counts Immediately Post-Exposure (Baseline-corrected), Ozone vs Filtered Air
|
-537.7 relative mRNA counts
Standard Deviation 3470
|
399.7 relative mRNA counts
Standard Deviation 5459
|
SECONDARY outcome
Timeframe: Baseline, immediately post-exposurePopulation: All participants that completed the study
Participants will be exposed to either filtered air (FA), then ozone (O3), or O3, then FA. Standard spirometry to obtain FEV1 and forced vital capacity (FVC) measurements will be done at baseline within two weeks prior to first exposure, and immediately after exiting the exposure chamber for each exposure. The % Predicted FVC will be calculated from measured versus expected values. The change in % Predicted FVC from baseline to immediately Post-Exposure will be calculated for each participant for each exposure. Values will be compared between FA and O3 to determine the effect of ozone on the % Predicted FVC.
Outcome measures
| Measure |
Filtered Air
n=14 Participants
Participants will be exposed to filtered clean air for 6.5 hours
|
Ozone
n=14 Participants
Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08 Parts Per Million (PPM)
|
|---|---|---|
|
The Percentage of Predicted Forced Vital Capacity (% Predicted FVC): Change Immediately Post-Exposure From Baseline
|
-0.3 percent predicted FEV1
Standard Deviation 0.7
|
-1.8 percent predicted FEV1
Standard Deviation 0.5
|
Adverse Events
Filtered Air
Ozone
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Michelle Hernandez, MD
UNC Center for Environmental Medicine, Asthma and Lung Biology
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place